SequelSEC

Inhibrx Biosciences, Inc. INBX

Biological Products, (No Diagnostic Substances) · CIK 0002007919 · Fiscal year ends 1231

Revenue
$1.30M
Fiscal year ended 2025-12-31
Operating income
-$135.02M
Fiscal year ended 2025-12-31
Free cash flow
-$129.82M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$174.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$11.95Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue134.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity21.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Long-term debt / equity12.58x96th
Revenue YoY growth550.0%93th
FCF margin-9986.5%11th
R&D / revenue8694.5%88th
Net margin-10773.5%13th
SBC / revenue856.8%86th
Operating margin-10386.5%14th
CapEx / revenue2.4%38th
Current ratio3.93x47th

Inhibrx Biosciences, Inc. (INBX) reported revenue of $1.30M and net income of -$140.06M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Inhibrx Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Inhibrx Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$1.30M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$135.02M
Net income-$140.06M
Research & development$113.03M
Weighted-average diluted sharesUnavailable
Pretax income-$140.05M
Income tax expense$2.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$23.30M
Selling & marketingUnavailable

Balance

Inhibrx Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$124.22M
Total assets$146.48M
Current assets$132.83M
Total liabilities$138.48M
Current liabilities$33.80M
Total equity incl. NCI$7.99M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debt$100.56M
Accounts payable$5.94M

Cash flow

Inhibrx Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$129.79M
Capital expenditures$31.00K
Investing cash flow-$28.00K
Financing cash flow$101.45M
Net change in cash-$28.38M
Stock-based compensation$11.14M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.48M

Derived

Inhibrx Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flow-$129.82M
Gross marginUnavailable
Operating margin-10386.5%
FCF margin-9986.5%
SBC / revenue856.8%
Current ratio3.93x
Revenue YoY growth550.0%
Net margin-10773.5%
R&D / revenue8694.5%
CapEx / revenue2.4%
Long-term debt / equity12.58x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INBX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.